(Q37402813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Mark Linch

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Robin L Jones

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Charlotte Benson

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Juan Martin-Liberal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Salma Alam

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Anastasia Constantinidou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Cyril Fisher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Christina Messiou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David Olmos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Scott Mitchell

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Omar Al-Muderis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Aisha Miah

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Michelle Scurr

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ian Judson

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

4 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

868973

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

3 March 2020

copyright license

start time

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Differential sensitivity of liposarcoma subtypes to chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Surgical management of primary and recurrent retroperitoneal liposarcoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Sex is a major determinant of CYP3A4 expression in human liver

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Gender difference in ifosfamide metabolism by human liver microsomes

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Sex is a major determinant of CYP3A4 expression in human liver

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867825

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

2 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2013%2F868973

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2013%2F868973

Stability of ifosfamide in solutions for multiday infusion by external pump

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24369450

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24369450

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24369450

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2013/868973

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

24369450

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24369450%20AND%20SRC:MED&resulttype=core&format=json